



Companies

Licensor
 Licensee

Potential Use

Disease Area
 Indication

Deal Financials

Potential Deal Size
 Upfront
 Milestones Total
 Milestones Regulatory
 Milestones Sales

Research Funding
 Profit Sharing Licensor
 Profit Sharing Licensee
 Royalties
 Equity

Compound

Compound Details
 Compound Name
 Development Stage

Territory
 Year of Deal Establishment
 Free Text Search

Filter Specification

275

OR

No.	Licensor	Potential Deal Size (mln) Amount	Upfront (mln) Remarks	Upfront (mln) Amount	Milestones total (mln) Remarks	Milestones total (mln) Amount	Milestones regulatory (mln) Remarks	Milestones regulatory (mln) Amount	Milestones sales (mln) Remarks	Milestones sales (mln) Amount	Research Funding (mln) Remarks	Research Funding (mln) Amount	Profit sharing Remarks	Profit sharing % licensor	Profit sharing % licensee	Ro % on Re
046	Astex Therapeutics	-	including 2 year research funding and equity	37.4	if 1 product per target (3) commer...	500	-	-	-	-	over 2 years including upfront and equity	37.4	-	0	0	Double tiered
047	Anylam Pharmaceuticals	-		5		51	-	-	-	-		-		0	0	
048	AstraZeneca (Cambridge Antibody Technology)	67	including 3 year research funding	12		-	-	-	-	-	over 3 years including upfront	12		0	0	
049	AstraZeneca (Cambridge Antibody Technology)	-	including technical performanc milest...	21.5	excluding technical performanc milestones	150	-	-	-	-	over 3 years	14.5		0	0	